Related Experiment Videos
Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV
Paul Pollack1, Jessie R Groothuis
1Global Research and Development, Abbott Laboratories, Abbott Park, IL, USA.
Insights
Palivizumab, a monoclonal antibody, effectively prevents respiratory syncytial virus (RSV) infections in high-risk infants. This treatment significantly reduces RSV-related hospitalizations, improving outcomes for vulnerable children.
Area of Science:
- Immunology
- Pediatrics
- Infectious Diseases
Background:
- Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections in infants globally.
- High-risk populations, including premature infants, those with cardiopulmonary conditions, and the immunosuppressed, face particularly severe RSV disease.
- Existing treatments for RSV have limited efficacy, highlighting the need for preventative measures.
Purpose of the Study:
- To review the preclinical development of palivizumab, a novel monoclonal antibody.
- To summarize the clinical experience and efficacy of palivizumab in preventing RSV infections.
- To evaluate palivizumab's role in reducing RSV-related hospitalizations in high-risk pediatric populations.
Main Methods:
- Review of preclinical studies detailing the genetic engineering and characterization of palivizumab.
- Analysis of clinical trial data assessing the safety and efficacy of palivizumab in preventing RSV.
- Evaluation of hospitalization rates associated with RSV in infants receiving palivizumab compared to placebo or standard care.
Main Results:
- Palivizumab, a genetically engineered monoclonal antibody, demonstrated effectiveness in preventing RSV infection.
- Significant reduction in RSV-related hospitalizations was observed in high-risk infants treated with palivizumab.
- Palivizumab represents a successful example of a genetically engineered therapeutic agent against a human infectious disease.
Conclusions:
- Palivizumab is a valuable tool for the prevention of respiratory syncytial virus lower respiratory tract infections.
- The use of palivizumab significantly decreases hospitalizations in vulnerable infant populations.
- This review underscores the importance of palivizumab in managing RSV in high-risk children.
Abstract:
Palivizumab (Synagis; Abbott Laboratories), a humanized, monoclonal antibody, prevents lower respiratory tract infection by respiratory syncytial virus (RSV). RSV causes significant morbidity and mortality in young children worldwide and is particularly severe in pre-term infants, children with cardiopulmonary disease, and the immunosuppressed population. The first such genetically engineered agent to be used effectively against a human infectious disease, palivizumab significantly reduces the number of hospitalizations caused by RSV in high-risk infants. This article reviews the preclinical development and clinical experience of palivizumab.